Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Green, Hefziba ^a   Paul, M ^b   Vidal, L ^b   Leibovici, L ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

*Immunocompromised host; Anti infective agents adverse effects; *therapeutic use ; Pneumonia, pneumocystis *prevention control ; Randomized controlled trials as topic

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ATOVAQUONE; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAPSONE; DAUNORUBICIN; FANSIDAR; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OFLOXACIN; PENTAMIDINE; PLACEBO; PYRIMETHAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIOGUANINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CHILDHOOD LEUKEMIA; COCHRANE LIBRARY; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; HEART TRANSPLANTATION; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOCOMPROMISED PATIENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER TRANSPLANTATION; MORTALITY; NEUTROPENIA; ORGAN TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 44949149229     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005590.pub2     Document Type: Review

References (70)

1. Arning 1990 {published data only} Arning M, Wolf HH, Aul C, Heyll A, Scharf RE, Scheider W. Infection prophylaxis in neutropenic patients with acute leukaemia - a randomized, comparative study with ofloxacin, ciprofloxacin and cotrimoxazole/colistin. Journal of Antimicrobial Chemotherapy 1990;26 Suppl D:137-42.
2. Colby 1999 {published data only} Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/ sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1999;24(8):897-902.
3. Fox 1990 {published data only} *Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. American Journal of Medicine 1990;89(3):255-74.
4. Maki DG, Fox BC, Kuntz J, Sollonger HW, Belzer OB. A prospective, randomised, double-blind study of thrimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. side effects of trimethoprim- sulfamethoxazole, interaction with cyclosporine. Journal of Laboratory Clinical Medicine 1992;119(1):11-24.
5. Goorin 1985 {published data only} Goorin AM, Hershey BJ, Levin MJ, Siber GR, Gelber RD, Flynn K, et al.Use of trimethoprim- sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatric Infection Disease 1985;4(3):265- 9.
6. Hibberd 1992 {published data only} Hibberd PL, Tolkoff-Rubin NE, Doran M, Delvecchio A, Cosimi AB, Delmonico FL, et al.Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. A double-blind, randomized controlled trial. Online Journal of Current Clinical Trials 1992;Doc No 15.
7. Hughes 1977 {published data only} Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJ, et al.Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. New England Journal of Medicine 1977;297(26):1419-26.
8. Hughes 1987 {published data only} Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. New England Journal of Medicine 1987;316(26):1627-32.
9. Liang 1990 {published data only} Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, et al.Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrobial Agents and Chemotherapy 1990;34(2):215-8.
10. Olsen 1993 {published data only} Olsen SL, Renlund DG, O'Connell JB, Taylor DO, Lassetter JE, Eastburn TE, et al.Prevention of Pneumocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation 1993;56(2):359-62.
11. Torre-Cisneros 1999 {published data only} Torre-Cisneros J, De la Mata M, Pozo JC, Serrano P, Briceno J, Solorzano G, et al.Randomized trial of weekly sulfadoxine/pyrimethamine vs. daily low-dose trimethoprim-sulfamethoxazole for the prophylaxis of Pneumocystis carinii pneumonia after liver transplantation. Clinical Infectious Disease 1999;29(4):771-4.
12. Van Eye 1987 {published data only} van Eys J, Berry DM, Crist W, Doering EJ, Fernbach DJ, Pullen J, et al.Effect of trimethoprim/ sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 1987;59(1):19-23.
13. Arend 1996 Arend SM, Westendorp RG, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, et al.Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clinical Infectious Disease 1996;22(6):920-5.
14. Arico 1992 Arico M, Molinari E, Bacchella L, DeAmici M, Raiteri E, Burgio GR. Prospective randomized comparison of toxicity of two prophylactic regimens of cotrimoxazole in leukemic children. Pediatric Hematology and Oncology 1992;9(1):35-40.
15. Carlin 1993 Carlin EM, Coker RJ, Goldin RD, Harris JR. Systemic Pneumocystis carinii pneumonia prophylaxis with dapsone and pyrimethamine fails to protect against extrapulmonary pneumocystosis. Genitourinary Medicine 1993;69(2):130-2.
16. Chung 2000 Chung JB, Armstrong K, Schwartz JS, Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis and Rheumatism 2000;43(8):1841-8.
17. Coker 1992 Coker RJ, Nieman R, McBride M, Mitchell DM, Harris JR, Weber JN. Co-trimoxazole versus dapsone-pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 1992;340(8827):1099.
18. Elinder 1992 Elinder CG, Andersson J, Bolinder G, Tyden G. Effectiveness of low-dose cotrimoxazole prophylaxis against Pneumocystis carinii pneumonia after renal and/or pancreas transplantation. Transplant International 1992;5(2):81-4.
19. Golden 1993 Golden JA, Katz MH, Chernoff DN, Duncan SM, Conte JE, Jr. A randomized comparison of once-monthly or twice-monthly highdose aerosolized pentamidine prophylaxis. Chest 1993;104(3):743-50.
20. Groll 2001 Groll AH, Ritter J, Muller FM. [Guidelines for Prevention of Pneumocystis carinii Pneumonitis in Children and Adolescents with Cancer]. Klinische Pediatrie 2001;213 Suppl 1:A38-49.
21. Holt 2000 Holt CD, Ingle G, Kunder G, Ghobrial RM, Busutti RW. Aerosolized pentamidine (APNT) compared to trimetoprim/sulfamethoxazole (MP/SMX) for pneumocystis carinii pneumonia prophylaxis (PCP) following orthotopic liver transplantation. 40th interscience conference on antimicrobial agents and chemotherapy. 2000.
22. Janner 1996 Janner D, Bork J, Baum M, Chinnock R. Pneumocystis carinii pneumonia in infants after heart transplantation. Journal of Heart and Lung Transplantation 1996;15(8):758-63.
23. Kramer 1984 Kramer BS, Carr DJ, Rand KH, Pizzo PA, Johnson A, Robichaud KJ, et al.Prophylaxis of fever and infection in adult cancer patients. A placebo-controlled trial of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer 1984;53(2):329-35.
24. Kramer 1992 Kramer MR, Stoehr C, Lewiston NJ, Starnes VA, Theodore J. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation - how effective and for how long?. Transplantation 1992;53(3):586-9.
25. Mallolas 1991 Mallolas J, Zamora L, Gatell JM, Miro JM, Soriano E. Lowdose co-trimoxazole, aerosolised pentamidine, or dapsone plus pyrimethamine for prevention of Pneumocystis carinii pneumonia. Lancet 1991;337(8750):1162-3.
26. Maschmeyer 1990 Maschmeyer G, Daenen S, de Pauw BE, de Vries-Hospers HG, Dekker AW, Donnelly JP, et al.Prevention of infection in acute leukemia. Haematology and Blood Transfusion 1990;33:525-30.
27. Mehta 1997 Mehta J, Powles R, Singhal S, Riley U, Treleaven J, Catovsky D. Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation. Leukemia and Lymphoma 1997;26(1-2):83-8.
28. Meyers 2001 Meyers B, Borrego F, Papanicolaou G. Pneumocystis carinii pneumonia prophylaxis with atovaquone in trimethoprim-sulfamethoxazole- intolerant orthotopic liver transplant patients: a preliminary study. Liver Transplantation 2001;7(8):750-1.
29. Moriuchi 1990 Moriuchi Y, Kamihira S, Satoh T, Yanagisako T, Miyazaki Y, Nagai K, et al.[Infection prophylaxis in patients with hematological malignancies (I) - Successful prophylaxis of Pneumocystis carinii pneumonitis with sulfamethoxazole-trimethoprim]. Rinsho Ketsueki 1990;31(11): 1818-22.
30. Mustafa 1994 Mustafa MM, Pappo A, Cash J, Winick NJ, Buchanan GR. Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole. Journal of Clinical Oncology 1994;12(2):258-61.
31. Nucci 2003 Nucci M, Andrade F, Vigorito A, Trabasso P, Aranha JF, Maiolino A. Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation. Transplant Infectious Disease 2003;5(4):167-73.
32. Okada 1999 Okada J, Kadoya A, Rana M, Ishikawa A, Iikuni Y, Kondo H. Efficacy of sulfamethoxazole-trimethoprim administration in the prevention of Pneumocystis carinii pneumonia in patients with connective tissue disease. Kansenshogaku Zasshi 1999;73(11):1123-9.
33. Pedagogos 1994 Pedagogos E, Nicholls K, Wilson J, Waiker R, Becker G. Comparison of oral trimethoprim/sulfamethoxazole (TM-SMX) and inhales pentamidine (P) for prevention of pneumocystis pneumonia (PCP) after renal transplantation. The Transplantation Society of Australia and New Zealand 1994.
34. Rossi 1987 Rossi MR, Banfi P, Cappuccilli M, Conter V, de Poli D, Piacentini G, et al.Prospective randomized comparison of two prophylactic regimens with trimethoprim-sulfamethoxazole in leukemic children: a two year study. European Journal of Cancer Clinical Oncology 1987;23(11): 1679-82.
35. Singer 1999 Singer NG, McCune WJ. Prevention of infectious complications in rheumatic disease patients: immunization, Pneumocystis carinii prophylaxis, and screening for latent infections. Current Opinion in Rheumatology 1999;11(3):173-8.
36. Slavin 1992 Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. Aids 1992;6(10):1169-74.
37. Souza 1999 Souza JP, Boeckh M, Gooley TA, Flowers ME, Crawford SW. High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis. Clinical Infectious Disease 1999;29(6):1467-71.
38. Stegeman 1996 Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. New England Journal of Medicine 1996;335(1):16-20.
39. Torre-Cisneros 1996 Torre-Cisneros J, de la Mata M, Lopez-Cillero P, Sanchez-Guijo P, Mino G, Pera C. Effectiveness of daily low-dose cotrimoxazole prophylaxis for Pneumocystis carinii pneumonia in liver transplantation - an open clinical trial. Transplantation 1996;62(10):1519-21.
40. Vasconcelles 2000 Vasconcelles MJ, Bernardo MV, King C, Weller EA, Antin JH. Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biology of Blood and Marrow Transplantation 2000;6(1):35-43.
41. Weinthal 1994 Weinthal J, Frost JD, Briones G, Cairo MS. Successful Pneumocystis carinii pneumonia prophylaxis using aerosolized pentamidine in children with acute leukemia. Journal of Clinical Oncology 1994;12(1):136-40.
42. Worth 2005 Worth LJ, Dooley MJ, Seymour JF, Mileshkin L, Slavin MA, Thursky KA. An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital. British Journal of Cancer 2005;92(5):867-72.
43. Young 1976 Young RC, DeVita VT, Jr. Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine. National Cancer Institute Monograph 1976;43:193-200.
44. Young 1987 Young LS, Hindler J. Use of trimethoprim- sulfamethoxazole singly and in combination with other antibiotics in immunocompromised patients. Review of Infectious Disease 1987;9 Suppl 2:S177-83.
45. Alderson 2004a Alderson P, Green S, Higgins JPT, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Appendix 5b. In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, Issue 3, 2005.
46. Alderson 2004b Alderson P, Green S, Higgins JPT, editors. Selection bias. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Section 6.3. In: The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd, Issue 3, 2005.
47. Alexander 2001 Alexander BD, Tapson VF. Infectious complications of lung transplantation. Transplant Infectious Diseases 2001;3:128-137.
48. Ellerin 2003 Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis and Rheumatism 2003;48:3013-22.
49. FDA 2001 FDA. Safety update on TNF-alfa antagonists: infliximab and etanerecept. Food and Drug Administration, Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting, 2001.
50. Fischl 1988 Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988;259:1185-89.
51. Freedberg 1998 Freedberg KA, Scharfstein JA, Seage GR, 3rd. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998;279:130-6.
52. Grimwade 2005 Grimwade K, Swingler G. Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV (review). Cochrane Database of Systematic Reviews 2003, Issue 3 Art. No.: CD003108. DOI:10.1002/ 14651858.CD003108.
53. Hagerty 2003 Hagerty JA, Ortiz J, Reich D, Manzarbeitia C. Fungal infections in solid organ transplant patients. Surgical Infections 2003;4:263-71.
54. Kaplan 1998 Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. Journal of Infectious Diseases 1998;178:1126-32.
55. Kaplan 2002 Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR. Morbidity and mortality weekly report 2002;51:1-52.
56. Kubak 2002 Kubak BM. Fungal infection in lung transplantation. Transplant Infectious Diseases 2002;4 Suppl 3:24-31.
57. Mandel 2004 Walzer PD, Smulian AG. Pneumocystis species. In: Mandel, Douglas and Bennet's principles and practice of infectious diseases. 6th Edition. Vol. 2, Churchill Livingstone, 2004:3080-94.
58. Mansharamani 2000 Mansharamani NG, Garland R, Delaney D, Koziel H. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000;118:704-11.
59. Moher 1998 Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported inmeta-analyses?. Lancet 1998;352(9128):609-13.
60. Patel 1997 Patel R, Paya CV. Infections in solid-organ transplant recipients. Clinical Microbiology Reviews 1997;10:86-124.
61. Raychaudhuri 1999 Raychaudhuri SP, Siu S. Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases. British Journal of Dermatology 1999;141:528-30.
62. Rodriguez 2004 Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clinical Microbiology Reviews 2004;17:770-82.
63. Schulz 1995 Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408- 12.
64. Sepkowitz 1993 Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clinical Infectious Diseases 1993;17(Suppl 2):S416-422.
65. Sepkowitz 2002 Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical Infectious Diseases 2002;34:1098-1107.
66. Stein 2004 Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerging Infectious Diseases 2004;10:1760-65.
67. Stringer 2002 Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerging Infectious Diseases 2002;8:891-6.
68. Thomas 2004 Thomas CF Jr, Limper AH. Pneumocystis pneumonia. New England Journal of Medicine 2004;350:2487-98.
69. Vargas 2001 Vargas SL, Hughes WT, Santolaya ME, Ulloa AV, Ponce CA, Cabrera CE, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clinical Infectious Diseases 2001;32:855-61.
70. Yale 1996 Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clinics Proceedings 1996;71:5-13.